Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

Clinical trial NCT07267806 · RECRUITING

Trial details

NCT number: NCT07267806
Sponsor: Linhui Peng
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hepato Cellular Carcinoma (HCC)Chemotherapy Effect

Start date: 2025-10-31
Primary completion: 2029-10-01
Enrollment: 326

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.